17 Dec 2021 Update on Regulatory Submission for Aducanumab in the European Union
17 Dec 2021 Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study
16 Dec 2021 Innate Pharma: First Patient Dosed in IPH6101/SAR443579 Phase 1/2 Clinical Trial in Various Blood Cancers
16 Dec 2021 AVT02, Alvotech’s Biosimilar to High Concentration Formulation of Adalimumab (Humira®) Approved for Use in European Union
16 Dec 2021 U.S. FDA grants Priority Review for spesolimab for the treatment of flares in patients with generalized pustular psoriasis (GPP), a rare, life-threatening skin disease
16 Dec 2021 Positive Top-Line Results for BIMZELX (bimekizumab) in Phase 3 Ankylosing Spondylitis Trial
15 Dec 2021 U.S. Food and Drug Administration Approves Orencia® (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)...
15 Dec 2021 Numab and 3SBio’s Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28
15 Dec 2021 Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
15 Dec 2021 TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
15 Dec 2021 Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022
14 Dec 2021 New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pre-treated Patients with Multiple Myeloma
14 Dec 2021 Ichnos Sciences and Almirall Enter into a Licensing Agreement for First-in-Class IL-1RAP Antagonist Monoclonal Antibody
14 Dec 2021 Coherus and Junshi Biosciences Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
14 Dec 2021 Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021
14 Dec 2021 Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition
14 Dec 2021 Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd American Society of Hematology Annual Meeting and Exposition
14 Dec 2021 Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody® and ADG152, a CD20xCD3 Bispecific T-cell Engager POWERbody™
14 Dec 2021 Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms
14 Dec 2021 Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition
14 Dec 2021 2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount
12 Dec 2021 Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition
12 Dec 2021 IGM Biosciences Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American Society of Hematology Annual Meeting
12 Dec 2021 ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome
12 Dec 2021 New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up